Skip to Main Content

The Trump administration has launched a comprehensive review of all research that involves fetal tissue, reopening an issue that has galvanized anti-abortion activists but worried scientists who fear their work could be under threat.

Fetal tissue has been used for a wide range of research in the U.S. since the 1930s, including the development of several vaccines and studies of genetic diseases. The tissue is obtained through elective abortions, and there are strict rules around how it can be procured and used.

advertisement

In a statement released late Monday, however, the Department of Health and Human Services said it would review whether current oversight of fetal tissue is adequate “in light of the serious regulatory, moral, and ethical considerations involved.” The agency also said it would terminate a contract with Advanced Bioscience Resources, a California-based nonprofit that supplies fetal tissue for scientific research, because of concerns that the contract did not include “appropriate protections” or meet “procurement requirements.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.